Search

Displaying results 4511 - 4520 of 7283 in total
  1. Drug

    Antihemophilic factor human

    go.drugbank.com/drugs/DB13192
    ApprovedInvestigational

    The small amount of VWF:Ag is used to purify factor VIII complex and then removed from the final preparation. The final purified concentrate contains albumin as a stabilizer.[L1053]. … Factor VIII, but does not contain the B-domain, which has no known biological function and [DB11607], which is a fully recombinant factor VIII-Fc fusion protein which has an extended half-life compared

    Mixtures: von Willebrand Factor/Coagulation Factor VIII Complex (Human), von Willebrand Factor/Coagulation Factor VIII Complex (Human)Categories: Hemophilia A
  2. Target

    Heat shock 70 kDa protein 13

    go.drugbank.com/bio_entities/BE0008957
    TargetHumans

    Has peptide-independent ATPase activity

    Synonyms: Microsomal stress-70 protein ATPase core
  3. Drug

    DS-2325a

    go.drugbank.com/drugs/DB18134
    Investigational

    DS-2325a is an inhibitor of kallikrein 5 under development for the treatment of Netherton Syndrome.

  4. Drug

    Sofosbuvir

    go.drugbank.com/drugs/DB08934
    ApprovedInvestigational

    Notably, sofosbuvir has come under intense scrutiny since its release to market in 2013. With the price per pill set at $1000, a 12-week treatment can cost upwards of $84,000 per patient [A19636]. … As a prodrug nucleotide analog, Sofosbuvir is metabolized into its active form as the antiviral agent 2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-triphosphate (also known as GS-461203), which acts as a defective

  5. Target

    Runt-related transcription factor 1

    go.drugbank.com/bio_entities/BE0010423
    TargetHumans

    Forms the heterodimeric complex core-binding factor (CBF) with CBFB. … RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'-TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory regions via their

    Synonyms: Core-binding factor subunit alpha-2, SL3/AKV core-binding factor alpha B subunit
  6. Target

    Protein S100-A8

    go.drugbank.com/bio_entities/BE0008955
    TargetHumans

    Activates NADPH-oxidase by facilitating the enzyme complex assembly at the cell membrane, transferring arachidonic acid, an essential cofactor, to the enzyme complex and S100A8 contributes to the enzyme … The iNOS-S100A8/A9 transnitrosylase complex directs selective inflammatory stimulus-dependent S-nitrosylation of GAPDH and probably multiple targets such as ANXA5, EZR, MSN and VIM by recognizing a [IL

    Synonyms: Leukocyte L1 complex light chain
  7. Drug

    Leukotriene D4

    go.drugbank.com/drugs/DB11858
    Investigational

    Leukotriene D4 has been used in trials studying the diagnostic of Asthma and Allergic Rhinitis.

    Categories: SRS-ASynonyms: Leukotriene D4
  8. Drug

    Faricimab

    go.drugbank.com/drugs/DB15303
    ApprovedInvestigational

    target VEGF-A. … [A225985, A225990, A225995] Vascular endothelial growth factor A (VEGF-A) is a well-known mediator of retinal NV, and many currently approved RVD therapies such as [aflibercept] and [ranibizumab] solely

  9. Drug

    Avatrombopag

    go.drugbank.com/drugs/DB11995
    ApprovedInvestigational

    [A33095] Thrombocytopenia is a common complication in patients suffering from chronic liver disease, occurring as a result of liver disease or a consequence of interferon-based antiviral therapy. … [F95] Avatrombopag was first approved by the FDA in May 2018 for use in adults with chronic liver disease who are scheduled to undergo a procedure.

  10. Drug

    DT-DEC01

    go.drugbank.com/drugs/DB19433
    Experimental

    DT-DEC01 is a novel Dystrophin Expressing Chimeric (DEC) cell therapy being investigated by Dystrogen Therapeutics Corporation.